CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Siegfried

Thomas Carl, Head Process R&D and Scale-Up

Expert Insights On The Future Of Process Development

Thomas Carl

Thomas Carl

In an interview with Life Sciences Review magazine, Carl provides valuable insights into the industry's evolving needs and the significance of emerging technologies in shaping its future.


Can you provide an overview of your professional journey, educational background and key roles and responsibilities at Siegfried?


I studied chemistry at the University of Stuttgart in Germany and the University of Reading in the UK. I pursued a PhD at the University of Basel, focusing on electron transfer in DNA and related methods. Following this, I pursued postdoctoral research at the University of California, Berkeley, working on the total synthesis of a complex molecule.


My career began in Switzerland with Ciba Specialty Chemicals, where I worked as a chemist for a new development project and later managed a group responsible for niche products. I also took on the roles of Deputy Plant Manager and Plant Manager during the merger with BASF. After my tenure at Ciba Speciality Chemicals, I joined Novartis as a senior process manager. Later, I shifted to SI Group, leading production and serving as the site director in Switzerland. Currently, with Siegfried, I've been heading the Chemical Development Process R&D and Scale-up for over four years, managing global responsibilities across Switzerland, Germany, and China.


With your extensive experience working at Siegfried, what challenges have you faced or are currently facing?


We face a significant challenge in process development due to the need to shorten project timelines. This has put immense pressure on us to deliver high-quality work within tighter schedules. At Siegfried, we've chosen an adaptive approach called the "toolbox approach," which combines digital simulations and real-world experiments to create custom-tailored developments.


Sustainability is another critical challenge, with increasing customer demands for greener processes. Nonetheless, we're actively redesigning processes to foster sustainability and facilitate cost-competitive second[1]generation processes.


How does your organization navigate the regulatory landscape to ensure compliance and safety during the process development?


 


Process safety is inherently integrated into process development at Siegfried. We conduct process safety investigations throughout the development process, employing techniques like differential scanning calorimetry and using reactor calorimeters to assess the behaviour and criticality of our processes. This early assessment helps identify potential safety issues and make necessary adjustments.Furthermore, we employ simulation tools to enhance safety. We also apply process analytical technologies(PAT) to design, analyze, and control our pharmaceutical manufacturing processes.


Are there any emerging technologies that you believe will play a significant role in shaping the future of process development?


While not entirely new, emerging technologies like flow chemistry and continuous processing, especially in downstream activities, are poised to reshape the future of process development. Batch distillation or batch extractions are lacking in the pharmaceutical industry, and there is potential for significant improvement. We’re also exploring ultrafiltration and nanofiltration techniques.


“We face a significant challenge in process development due to the need to shorten project timelines. This has put immense pressure on us to deliver high-quality work within tighter schedules”


Additionally, we're focused on integrating Process Analytical Technologies (PAT) on a larger scale to gain real-time insights and make data-driven decisions, improving process control. Simulation tools for crystallization and other processes are also becoming more sophisticated and valuable in process development.


Do you have any advice for other senior leaders and CMOs in the industry?


My advice for senior leaders in the industry and CMOs is to have confidence in your capabilities and expertise. In the face of tight schedules, it's essential to recognize your strengths and know what you can handle. Build expertise within your organization and embrace new ideas and technologies, even if they require effort to implement, as these innovations can lead to significant improvements in quality, efficiency, and sustainability. Being self-confident and proactive in offering innovative solutions can set you apart and provide substantial benefits to the industry and customers.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/expert-insights-on-the-future-of-process-development-nwid-1639.html